Annonce

Log ud Log ind
Log ud Log ind
Ledelse

US sundhedsmyndighed FDA vil ikke have åbenhed om Pfizer-vaccinedata før år 2076

Morten W. Langer

torsdag 18. november 2021 kl. 16:29

by attorney Aaron Siri

The FDA has asked a federal judge to make the public wait until the year 2076 to disclose all of the data and information it relied upon to license Pfizer’s COVID-19 vaccine. That is not a typo. It wants 55 years to produce this information to the public.

As explained in a prior article, the FDA repeatedly promised “full transparency” with regard to Covid-19 vaccines, including reaffirming “the FDA’s commitment to transparency” when licensing Pfizer’s COVID-19 vaccine.

With that promise in mind, in August and immediately following approval of the vaccine, more than 30 academics, professors, and scientists from this country’s most prestigious universities requested the data and information submitted to the FDA by Pfizer to license its COVID-19 vaccine.

The FDA’s response?  It produced nothing. So, in September, my firm filed a lawsuit against the FDA on behalf of this group to demand this information. To date, almost three months after it licensed Pfizer’s vaccine, the FDA still has not released a single page. Not one.

Instead, two days ago, the FDA asked a federal judge to give it until 2076 to fully produce this information. The FDA asked the judge to let it produce the 329,000+ pages of documents Pfizer provided to the FDA to license its vaccine at the rate of 500 pages per month, which means its production would not be completed earlier than 2076.  The FDA’s promise of transparency is, to put it mildly, a pile of illusions [ZH, we note that the FDA justifies this by claiming that the rate of 500 pages per month “is consistent with processing schedules entered by courts across the country in FOIA cases,” and blames the plaintiffs for “its own broad FOIA request”].

It took the FDA precisely 108 days from when Pfizer started producing the records for licensure (on May 7, 2021) to when the FDA licensed the Pfizer vaccine (on August 23, 2021).   Taking the FDA at its word, it conducted an intense, robust, thorough, and complete review and analysis of those documents in order to assure that the Pfizer vaccine was safe and effective for licensure. While it can conduct that intense review of Pfizer’s documents in 108 days, it now asks for over 20,000 days to make these documents available to the public. 

So, let’s get this straight. The federal government shields Pfizer from liability.  Gives it billions of dollars.  Makes Americans take its product.  But won’t let you see the data supporting its product’s safety and efficacy.  Who does the government work for?

The lesson yet again is that civil and individual rights should never be contingent upon a medical procedure.  Everyone who wants to get vaccinated and boosted should be free to do so.  But nobody should be coerced by the government to partake in any medical procedure.  Certainly not one where the government wants to hide the full information relied upon for its licensure until the year 2076!

Tilmeld dig vores gratis nyhedsbrev
ØU Bestyrelsesguiden

Få de vigtigste nyheder om praktisk bestyrelsesarbejde, ledelse og strategi i SMV.
Udkommer hver onsdag.

Jeg giver samtykke til, at I sender mig mails med de seneste historier fra Økonomisk Ugebrev. Lejlighedsvis må I gerne sende mig gode tilbud og information om events. Samtidig accepterer jeg ØU’s Privatlivspolitik.

Du kan til enhver tid afmelde dig med et enkelt klik.

[postviewcount]

Jobannoncer

No data was found

Mere fra ØU Ledelse

Log ind

Har du ikke allerede en bruger? Opret dig her.

*Tilbuddet gælder ikke, hvis man har været abonnent indenfor de seneste 6 måneder

Tilmeld dig vores nyhedsbrev

Og modtag ØU’s rapport om Top 40 Ledelseskonsulenter gratis.

FÅ VORES STORE NYTÅRSUDGAVE AF FORMUE

Her er de 10 bedste aktier i 2022

Tilbuddet udløber om:
dage
timer
min.
sek.

Analyse af og prognoser for Fixed Income (statsrenter og realkreditrenter)

Direkte adgang til opdaterede analyser fra toneangivende finanshuse:

Goldman Sachs

Fidelity

Danske Bank

Morgan Stanley

ABN Amro

Jyske Bank

UBS

SEB

Natixis

Handelsbanken

Merril Lynch 

Direkte adgang til realkreditinstitutternes renteprognoser:

Nykredit

Realkredit Danmark

Nordea

Analyse og prognoser for kort rente, samt for centralbankernes politikker

Links:

RBC

Capital Economics

Yardeni – Central Bank Balance Sheet 

Investing.com: FED Watch Monitor Tool

Nordea

Scotiabank